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Alveolar soft part sarcoma (ASPS), a deadly soft tissue malignancy with a 
predilection for adolescents and young adults, associates consistently with t(X;17) 
translocations that generate the fusion gene ASPSCR1-TFE3. We proved the 
oncogenic capacity of this fusion gene by driving sarcomagenesis in mice from 
conditional ASPSCR1-TFE3 expression. The completely penetrant tumors were 
indistinguishable from human ASPS by histology and gene expression. They formed 
preferentially in the anatomic environment highest in lactate--the cranial vault--, 
expressed high levels of lactate importers, harbored abundant mitochondria, 
metabolized lactate as a metabolic substrate and responded to the administration of 
exogenous lactate with tumor cell proliferation and angiogenesis. These data 
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 Significance 
By conditionally expressing in mice the fusion gene ASPSCR1-TFE3 from human 
alveolar soft part sarcoma (ASPS), we generated a model that recapitulates the human tumor 
histologically and molecularly with remarkable fidelity, enabling study of the conditions 
supportive of tumor development. Mouse tumors demonstrated angiogenic gene expression in 
the frank absence of hypoxia and were restricted to the tissue compartments highest in lactate. 
They expressed high levels of lactate transport proteins (MCT1s), and responded to exogenous 
lactate with robust proliferation and angiogenesis. Such lactate metabolism in a malignancy has 
been previously postulated, but never before available for direct investigation in an in vivo 
tumorigenesis model. Interventions targeting lactate metabolism may provide novel therapeutic 
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Highlights 
 The alveolar soft part sarcoma fusion ASPSCR1-TFE3 drives tumorigenesis in 
mice. 
 Mouse tumors from ASPSCR1-TFE3 mimic human sarcomas by histology and 
transcriptome. 
 Alveolar soft part sarcomas demonstrate high Hif1α and angiogenesis without 
hypoxia. 
 Their anatomy and response to exogenous lactate suggest tumors metabolize 
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Introduction 
Approximately one-third of all sarcomas, the cancers of connective tissue, 
associate with chromosomal translocations that generate fusion genes (Helman and 
Meltzer, 2003). Many of these fusion genes have been shown to serve as primary 
drivers of sarcomagenesis (Haldar et al., 2007; Keller et al., 2004; Perez-Losada et al., 
2000; Straessler et al., 2013). Alveolar soft part sarcoma (ASPS), a deadly soft tissue 
malignancy of enigmatic origin, consistently demonstrates a t(X;17)(p11.2;q25) 
translocation that produces the fusion gene ASPSCR1-TFE3 (Ladanyi et al., 2001). 
 ASPS presents most frequently in the adolescent or young adult limb, often 
metastasizes, and generally proves resistant to chemotherapy (Folpe and Deyrup, 
2006). First described in 1951 (Smetana and Scott, 1951), these highly vascular tumors 
demonstrate characteristic histomorphology, comprised of organoid nests of polygonal 
tumor cells separated by fibrovascular septa with delicate capillary arcades (Folpe and 
Deyrup, 2006). ASPSs also demonstrate distinct, granular structures in the cytoplasm of 
some cells (Ladanyi et al., 2002). 
Using the few available cell lines and analysis of human ASPS tumor specimens, 
it has been shown that the ASPSCR1-TFE3 fusion protein functions as a master 
regulatory transcription factor, joining a yet-to-be deciphered activation motif from 
ASPSCR1 to the DNA-binding domain of the TFE3 transcription factor from the MITF 
family (Covell et al., 2012; Kummar et al., 2013; Ladanyi et al., 2001; Stockwin et al., 
2009). Although many angiogenic genes are highly upregulated in the tumors (Lazar et 
al., 2007; Vistica et al., 2009), few were found to be direct transcriptional targets of the 
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suggests that some other factor, possibly related to metabolism or microenvironment, 
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Generation of an inducible mouse allele of ASPSCR1-TFE3 
In order to characterize the fusion gene associated with ASPS and its role in 
sarcomagenesis, we created a novel mouse allele designed to express ASPSCR1-
TFE3 conditionally. Briefly, the Rosa26-LSL-AT3 allele was generated by isolating the 
type 2 ASPSCR1-TFE3 fusion gene transcript from total RNA obtained from a human 
ASPS. The complete complementary coding sequence (cDNA) was placed in the 
Rosa26 locus separated from the native promoter by a stop sequence, flanked by loxP 
sites (LSL), that is conditionally removed via Cre-mediated recombination. The fusion 
gene cDNA was followed by coding sequence for the enhanced green fluorescent 
protein (eGFP), linked by an internal ribosomal entry site (IRES) to permit tandem 
expression of eGFP whenever ASPSCR1-TFE3 was expressed (Fig.1A). 
To validate the conditional character of the LSL-AT3 allele, heterozygous E12.5 
fibroblasts were harvested, dissociated, and cultured, then exposed either to vehicle 
control or TATCre, a protein version of Cre-recombinase with the TAT moiety from the 
human immunodeficiency virus that enables transport through the cell membrane and 
localization to the nucleus (Joshi et al., 2002; Straessler et al., 2013). After 48 hours, 
cells exposed to TATCre, but not control conditions, fluoresced (Fig.1B). Reverse 
transcriptase polymerase chain reaction (RT-PCR) also confirmed the presence of the 
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ASPSCR1-TFE3 expression leads to rapid, anatomically restricted tumorigenesis 
Considering possible tumorigenesis in a comparative context, mice homozygous 
for conditional AT3, as well as other mice homozygous for previously described 
conditional SS18-SSX2 (synovial sarcoma) (Haldar et al., 2007) and EWSR1-ATF1 
(clear cell sarcoma) (Straessler et al., 2013) were bred to mice bearing a tamoxifen-
inducible Cre-recombinase also driven from the Rosa26 locus (Mao et al., 1999). It has 
been previously noted that in the absence of tamoxifen, a small portion of cells in most 
tissues in the mouse will undergo Cre-mediated recombination from nuclear entry of the 
CreER (Haldar et al., 2007; Straessler et al., 2013). We used it in this fashion as a low-
prevalence, but random tissue initiator of expression. 
In the comparative cohorts, Rosa26-LSL-EWSR1-ATF1/CreER mice demonstrated clear 
cell sarcoma mimicking tumors across a broad anatomic distribution in the 3-6 month 
age range. Rosa26-LSL-SS18-SSX2/CreER mice manifested a similar anatomic distribution of 
synovial sarcoma mimicking tumors, but following a longer latency of closer to a year. 
Rosa26-LSL-AT3/CreER mice developed either unusual behavior or a visibly enlarging 
occiput between 3 and 6 months of age. On necropsy, every mouse was noted to have 
developed a tumor within the skull (Fig.2A-B).  
Rosa26-LSL-AT3/CreER mice often demonstrated enlargement of the occipital bone 
from inner soft tissue expansion (Fig.2C-D). Slightly pink colored tumors (Fig.2E-F) 
were found primarily in the brain parenchyma, but also in the choroid plexus and orbit 
(Fig.2.I-K). The AT3-induced tumors fluoresced (Fig.2G-H), indicating eGFP and 
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Mouse tumors from ASPSCR1-TFE3 mimic human ASPS histopathology 
We next determined whether or not the tumors induced by the conditional AT3 
allele recapitulated human ASPS histopathologically. Hematoxylin and eosin (H&E) 
staining of a panel of human ASPS and Rosa26-LSL-AT3/CreER mouse tumors 
demonstrated the characteristic nests of polygonal cells with an open chromatin pattern, 
surrounded by neatly arcading capillary and larger vascular channels (Fig.3A-D). The 
species of origin for each slide was microscopically indistinguishable by an expert 
sarcoma-focused pathologist. 
Diastase treatment of sections followed by periodic acid Schiff (dPAS) 
histochemical staining produces a pathognomic pattern in ASPS. In mouse tumors, 
dPAS demonstrated the characteristic granular deposits classically described in human 
ASPS (Fig.3E-F).  
Many clinical labs use immunohistochemical staining against TFE3 as a 
surrogate marker for the fusion (Argani et al., 2003). We submitted human ASPS, 
Rosa26-LSL-AT3/CreER, and Rosa26-
LSL-SS18-SSX2/CreER tumor sections to our clinical 
laboratory. Both human and mouse tumors associated with ASPSCR1-TFE3 
demonstrated the diagnostic, strong nuclear TFE3 staining (Fig.3G-H), whereas mouse 
tumors driven by SS18-SSX2 provided the appropriate negative control (data not 
shown). 
Tumors induced by conditional AT3 expression in the mouse often arose in or 
near the leptomeninges, along sulci (Fig.3I).  Some tumors showed a broad, pushing 
front that maintained the pia mater layer between tumor and surrounding brain 
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distinct extensions of tumor cells into the cerebellum, cerebrum, and the vessels of the 
choroid plexus (Fig.3K-M). Invasive foci were often invested with capillaries (Fig.3N), 
which may represent tumor-induced vessels or microvascular invasion. 
 
The ASPSCR1-TFE3-driven mouse tumor transcriptome mimics human ASPS 
In order to further validate the tumors generated by conditional AT3 expression 
as a model for human ASPS, we performed a series of transcriptomic analyses. 
Iterative alignment of gene expression profiles between mouse and human tumors from 
multiple series has proven fruitful in the past to identify the unique expression signature 
of a given tumor type (Haldar et al., 2007). Such analyses are best performed with a 
common control tissue as a sounding board or background for each tumor 
transcriptome. Because most human ASPSs arise within skeletal muscles, and high 
quality muscle samples could be obtained from both mice and humans, we selected 
skeletal muscle as our comparative control, even though it was clear that the mouse 
tumors did not arise from muscle. 
Sequencing of cDNA libraries prepared from total RNA (RNAseq) from 5 
histologically- and translocation-confirmed human ASPSs, 3 human skeletal muscle 
samples, 5 Rosa26-LSL-AT3/CreER induced mouse tumors, and 3 mouse skeletal muscle 
samples yielded species-specific alignments that could be compared after filtering and 
re-assigning mouse genes onto human homologues. Cross species gene set 
enrichment analysis (GSEA) was then performed for the 500 most significantly up-
regulated and 500 most significantly down-regulated genes in each intra-species tumor 
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enrichment for the up-regulated gene sets (FDR q-value < 0.0005 for each GSEA) and 
no enrichment for the down-regulated gene sets (FDR q-value = 1.0 for all. Fig.4A). This 
was repeated for the 2nd through 5th groups of 500 most up-regulated genes from the 
human RNAseq comparison in the mouse samples, such that all genes at least two-fold 
significantly up-regulated were tested. All 5 of these gene sets were significantly 
enriched in the mouse tumor to muscle gene ranking with NES > 1.8 and FDR q-value < 
0.0005 for each. Such enrichment of homologous genes suggests a strong 
transcriptomic match between the mouse model and human ASPS. 
For an external validation, microarray-derived expression profiles on the 
Affymetrix Human Genome U133 Plus 2.0 Array from 7 human ASPSs and 5 human 
skeletal muscle control samples were obtained from the Gene Expression Omnibus 
(GEO) records GSE13433 and GSE34111. Each list of up-regulated genes was 
significantly enriched by GSEA in comparison across species and RNAseq versus 
microarray platforms (FDR q-value < 0.0005 for each). Each list of down-regulated 
genes showed no enrichment (FDR q-value = 1.0 for each. Fig.4A). As a second 
external validation, we evaluated the expression of the 51 human genes found by 
Kobos et al. to be upregulated in multiple human series and whose promoters were 
found to be bound by the fusion oncoprotein in chromatin immunoprecipitation 
experiments.  45 of these genes were at least 1.5-fold up-regulated in mouse tumors 
compared to mouse muscles. 
In order to determine a species transcendent ASPSCR1-TFE3 gene expression 
signature, we identified all human genes or mouse homologues that were at least 2-fold 
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comparisons (Supplemental Table 1). A heatmap of these 539 unique genes, 
contrasting log2 transformed fold-changes of tumors versus controls (Fig.4B) showed 
consistently high expression across individual tumors samples from each group. Finally, 
assessment of the character of these consistently up-regulated genes by GO-Elite 
analysis noted carbohydrate metabolism, cell division, and cell cycle as the most 
significant biological process gene ontologies (Fig.4C). 
 
ASPSCR1-TFE3 expression leads to spatially restricted tumorigenesis even 
among different cell lineages 
The observation that tumors in Rosa26-LSL-AT3/CreER mice recapitulated human 
ASPS features so clearly by histopathology and transcriptomic analysis only enhanced 
our notice of the striking difference between the two species in anatomic distribution. 
Whereas most human ASPSs arise in skeletal muscle, none of the Rosa26-LSL-AT3/CreER 
mice developed tumors in the skeletal muscle. This contrasted with our comparison 
mouse genetic cancer models which actually favored development of tumors within 
skeletal muscles, despite expressing their respective fusion genes from the identical 
locus and initiated by the same driver of Cre-recombinase (Fig.2B).  
Suspecting that the mouse brain might harbor some preferred cell of origin for 
transformation by AT3 expression, leading to tumorigenesis that was too rapid to allow 
slower limb tumors to become detectable, we next crossed mice bearing conditional 
AT3 with mice bearing a lineage-restricted tamoxifen-inducible Cre-recombinase, 
expressed from a Prx1 promoter (Prx1-CreERT2) (Hasson et al., 2007). Prx1-CreERT2 
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periosteal mesenchyme, but also includes some intramuscular pericytes (Kawanami et 
al., 2009; Logan et al., 2002; Straessler et al., 2013). Prx1-CreERT2;Rosa26LSL-AT3/wt 
mice consistently developed intracranial tumors 10-14 weeks after tamoxifen at age 2 
weeks. Interestingly, tumors were located either within the brain parenchyma or in the 
periosteum along the inner table of the cranium (Fig.5A). No tumors were identified in 
the outer table periosteum or the limbs, where most of the post-natal Prx1 lineage is 
found. 
Prx1 expression in neural stem cells has been previously described (Shimozaki 
et al., 2013). We have also previously shown the lineage to include perivascular 
mesenchymal cells (Straessler et al., 2013). Either of these portions of the Prx1 lineage 
might explain the intra-parenchymal tumors, but the periosteal tumors presented a 
conundrum. First, these periosteal cells of origin were decidedly not within the brain 
parenchyma, ruling out our initial suspicion of a preferred cell of origin in that host 
tissue.  Second, the periosteal lineage (including mesenchymal progenitors to both 
osteochondral and endothelial differentiation) should not be different morphologically on 
the inner surface of the cranium than outside the cranium.  
To compare the presence of the lineage on the inner table of the cranial 
periosteum, we crossed Prx1-CreERT2 bearing mice to mice bearing a Rosa26-LSL-
LacZ reporter allele (Soriano, 1999). X-gal staining of 3 week old 
Prx1CreERT2;Rosa26LSL-LacZ/wt mouse brains post receipt of tamoxifen at 2 weeks 
demonstrated periosteal staining along the inner and outer tables of the cranium as well 
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Notably, the extra-cranial periosteum stained just as consistently as did the intra-
cranial periosteum with lineage tracing, but only the latter gave rise to tumors in 
Prx1CreERT2;Rosa26LSL-AT3/wt mice. The spatially restricted development of periosteal 
tumors intra- but not extra-cranially suggested that something unique to the 
microenvironment inside the cranial vault enhanced at least the efficiency of 
tumorigenesis there. 
 
ASPSCR1-TFE3 tumors are primed to import lactate 
To triangulate our thinking about the microenvironment pertinent to intracranial 
mouse tumors and human ASPSs in skeletal muscle, we returned to what both species’ 
tumors had in common:  deranged carbohydrate metabolism (Fig.4C).  Both brain and 
muscle have been the primary tissues of focus in the elucidation over recent decades of 
the phenomenon termed lactate flux (Brooks and Gaesser, 1980; Gladden, 2008). 
Some cells either temporarily or consistently export lactate produced by glycolysis. 
Other cells (in nearby or distant tissues accessed through the circulation) import and 
metabolize that lactate. While muscle can demonstrate a high volume lactate flux during 
activity, the brain consistently moves lactate between cells via the astrocyte-neuron 
shuttle (Aubert et al., 2005).  
Significant lactate import requires elevated interstitial or intravascular lactate and 
the expression of monocarboxylate transporters (MCTs). Although lactate can cross 
membranes via other means, MCTs are responsible for the bulk of lactate transport. 
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import lactate; MCT4 is highly expressed in tissues that primarily export lactate 
(Halestrap, 2013).  
We assessed the raw RNAseq expression levels (in fragments per kilobase of 
exon per million fragments mapped, or FPKM units) of monocarboxylate transport 
genes in tumors and muscles. The muscle provided an ideal comparison control tissue, 
as skeletal muscle is known to express high levels of lactate transport genes. The two 
genes comprising the lactate transport complex associated with lactate importation, 
Mct1 and Cd147, were very highly over-expressed in tumors compared to muscles or 
compared to any other monocarboxylate transport genes in the tumors (Fig.6A). This fit 
the previously reported immunohistochemical finding of these two proteins in the 
cytoplasmic crystals stained by dPAS in human ASPS (Ladanyi et al., 2002). Further, 
Mct4, the transport gene associated with lactate exportation, was not only expressed at 
a much lower level in tumors than the import-associated complex, but also at a 
significantly lower FPKM than in muscle.  
MCTs are not pumps; their function requires lactate available for import. We 
therefore biochemically measured the lactate concentration in a panel of tissues in 
normal 2 month-old mice. Brain and eye, the host tissue compartments of all the AT3-
driven tumors, demonstrated the highest tissue lactate concentrations (Fig.6B).  
 
Lactate serves as a metabolic substrate in ASPSCR1-TFE3 tumors 
In order for imported lactate to contribute to metabolism, the cell would have to 
have significant oxidative capacity. As a measure of the abundance of mitochondria, we 
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mitochondria, using the Broad Institute's MitoCarta list. Again, the comparison control of 
muscle was fortuitous in that muscle exhibits one of the highest mitochondrial contents 
in normal mammalian tissues. Surprisingly, ASPSCR1-TFE3-driven tumors 
demonstrated dramatic up-regulation of nearly the entire complement of mitochondrial 
genes compared to quadriceps muscle controls, in both mouse and human 
comparisons (Fig.7A-B). 
We also measured the oxygen consumption of fresh tissue sections from AT3-
driven mouse tumors compared to other tumor controls, both at baseline in minimal 
media and following administration of lactate substrate. ASPSCR1-TFE3-driven mouse 
tumors were more oxidative than comparison mouse tumor types at baseline and 
responded oxidatively to the administration of lactate substrate (Fig.7C-D). 
 
Lactate serves as a signaling molecule in ASPSCR1-TFE3 tumors 
While considered to be induced by hypoxia through down-regulation of its 
hydroxylation and proteosomal degradation at low oxygen levels, HIF1α also directly 
responds to lactate levels within a cell (Fig.8A) (Burns and Wilson, 2003; Kumar et al., 
2007; Xiong et al., 1998). Needless to say, this phenomenon contributes to the hypoxic 
stabilization of HIF1α, as intracellular lactate accumulates in hypoxia, but does not 
strictly require hypoxia itself.  
It has been previously shown that human ASPS has high levels of HIF1α 
(Kenney et al., 2011; Stockwin et al., 2009; Vistica et al., 2009). If these levels were 
generated in response to imported lactate, as opposed to lactate produced within the 
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the tumors by administering pimonidazole to tumor-bearing Rosa26-LSL-AT3/CreER mice 
prior to euthanasia. Only in the presence of hypoxia (oxygen tensions lower than 10 
torr) will pimonidazole form adducts with thiol groups that are detectable by 
immunohistochemistry with an available monoclonal antibody (Rosenberger et al., 
2009).  
Control tissues of the kidney, liver, brain, and skin were collected as well as 
tumors from each mouse. While the normal prevalence of pimonidazole adducts and 
therefore hypoxia was detected in each of the control tissues, few tumors demonstrated 
any hypoxia (Fig.8B). Tumors demonstrated less hypoxia than even the surrounding 
normal brain parenchyma.  
Normal tissues showed demonstrable Hif1α immunohistochemistry only in 
hypoxic regions, such as the renal tubules. In contrast, tumors demonstrated strong 
nuclear Hif1α staining throughout (Fig.8B), despite normoxia. Signaling from imported 
lactate can increase levels of Hif1α in normoxia. We further tested these thoroughly 
non-hypoxic tumors for expression of a “hypoxic” gene signature and found them to 
demonstrate enrichment (Fig.8C), possibly reflecting other indirectly lactate-responsive 
genes. 
In order to test the hypothesis that ASPSCR1-TFE3 tumors receive signaling 
from imported lactate, we administered lactate or saline by daily isotonic intraperitoneal 
(IP) injections for two weeks prior to sacrifice in a subset of mice that had developed 
tumors. Exogenous lactate drove dramatic increases in proliferative index and vascular 
density (Fig.8D-F). As cross-validation of this effect, we cultured the only two described 
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Kobos et al., 2013) and ASPS-1 (Kenney et al., 2011) in increasing concentrations of 
sodium lactate, identifying a proliferative response. We further confirmed that increased 
exogenous lactate concentration in normoxia drove higher HIF1α stabilization, 
evidenced by its increased nuclear presence.  This effect was blocked by tandem 
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Discussion 
We report a genetic model of alveolar soft part sarcomagenesis and have 
validated its mimicry of human tumors with both histologic and transcriptomic analyses. 
This model revealed a very unusual anatomic distribution, which has implications with 
regard to cell of origin and the metabolic microenvironment. Despite the already 
reported high expression of Hif1α and pro-angiogenic genes in ASPS, we demonstrated 
that these tumors lack frank hypoxia. When provided exogenous administration of 
lactate, the tumors responded with enhanced proliferation and dramatic angiogenesis, 
suggesting that lactate, not hypoxia, contributes to this unique form of sarcomagenesis. 
 
Alveolar soft part sarcomagenesis is driven by its translocation-generated fusion 
oncogene 
Previously, members of our group have demonstrated the oncogenicity of the 
fusion genes that derive from chromosomal translocations in alveolar 
rhabdomysarcoma (PAX3-FKHR) (Keller et al., 2004), synovial sarcoma (SS18-SSX2) 
(Haldar et al., 2007), and clear cell sarcoma (EWSR1-ATF1) (Straessler et al., 2013). 
Others have shown a similar transformation in the mouse by the FUS-CHOP fusion 
oncogene associated with myxoid liposarcoma (Perez-Losada et al., 2000). By using a 
Cre/loxP conditional construct in the Rosa26 locus to drive expression of ASPSCR1-
TFE3, we have now shown this fusion gene to be sufficient for completely penetrant 
oncogenesis in the mouse. 
Remarkably, the AT3-driven mouse tumors were histopathologically well 
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Expression profiles were also stridently parallel between mouse and human tumors. 
Such interspecies comparisons have been fraught with difficulty in the past. We have 
previously utilized RNAseq as a less platform-constrained means of understanding the 
transcriptome of mouse tumor models (Straessler et al., 2013), but never before had 
human tumor RNAseq data for comparison, as we had in these analyses. In addition to 
our primary data, we also incorporated a prior microarray-based study of human ASPS 
gene expression and another chromatin immunoprecipitation analysis to further validate 
our primary RNAseq results. 
Taken together, these results from both gene expression and histopathology 
argue that in a manner similar to synovial sarcoma and clear cell sarcoma, the 
complicated biology of ASPS initiation is recapitulated by mere expression of its fusion 
gene ASPSCR1-TFE3. Importantly, none of these genetic mouse models driven by 
expression of translocation-generated fusion oncogenes fully recapitulates the most 
advanced clinical stages of its related human sarcoma. In addition to the lack of overt 
metastases, shared by all of the above models, this ASPS model also lacks 
histologically clear vascular invasion, which is commonly identified in the human 
counterpart. However, the intra-cranial location of the tumors in our model somewhat 
complicates this analysis. Possibly, such aggressive features of disease require more 
time or larger tumor size than can be endured by mice. Notably, this emphasizes that 
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Alveolar soft part sarcomagenesis is anatomically restricted in humans and mice 
While the cell of origin of this unique tumor has long been controversial, our 
studies lend some new insights to the debate. Prior arguments have typically centered 
on either a myogenic or neural cell of origin, depending on gene expression in tumors 
as evidence of histogenesis. The formation of mouse tumors in intra-cranial tissue 
compartments that completely lack skeletal muscle removes the possibility of an 
exclusively skeletal muscle cell of origin. Of course, the same can be deduced from the 
human ASPSs described to have arisen primarily within the cranial vault (Bodi et al., 
2009; Das et al., 2012) or cardiac muscle (Luo et al., 2008). Instead of confirming either 
muscle or neural origins, our experiments with the Prx1 lineage argue that some 
mesenchymal progenitor, possibly pericyte/endothelial in character, provides one 
potential cell of origin distinct from either previously considered lineage. Because 
pericytes are ubiquitous throughout the body, the specific locations of tumors could not 
be explained by the availability of a cell of origin alone. However, a pericyte cell of origin 
in humans could explain the occasional ASPS tumor reported to arise in an unusual 
anatomic location. 
We interpret the anatomic location of mouse tumors induced by expression of 
ASPSCR1-TFE3 as circumstantial evidence of a preference for high environmental 
lactate. While this predilection for origin within the brain in the mouse is not 
recapitulated in human ASPSs, all the tissues which play common host to human ASPS 
are also thought to be high lactate tissues, such as skeletal muscle, cardiac muscle, 
and brain. Most human ASPSs arise in the skeletal muscle of active adolescents and 
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is the most frequently (per its low prevalence) either metastatic or primary to the brain 
(Fox et al., 2009). While the prevalence of ASPS comprises about 1 percent of all 
sarcomas, it is the most common among primary or metastatic cardiac sarcomas in 
clinical series as well (Agaimy et al., 2012; Kumar et al., 2011). Interestingly, evidence 
from different experimental approaches has shown that the heart can get up to 60 
percent of its energy from lactate oxidation (Gertz et al., 1988; Gladden, 2008; Stanley, 
1991). While ASPS is not strictly considered to arise in the kidney--another high lactate 
tissue--a special subset of renal cell carcinomas express and are thought to be driven 
by the ASPSCR1-TFE3 fusion gene and other TFE3 fusions (Argani et al., 2001). Much 
of ASPS biology has actually been inferred from studies in a clear cell carcinoma cell 
line that expresses ASPSCR1-TFE3 (Ishiguro et al., 2004).   
Some other information can be gleaned regarding lactate in the 
microenvironment from prior attempts to directly xenograft human ASPSs into the 
subcutaneous flanks of immnocompromised mice. Attempts with 12 different tumors 
yielded four successes at a latency of 8-9 months; three of those successes derived 
from lung or lymph node metastases (Vistica et al., 2009). While these data argue that 
ASPS can grow in host tissues lacking overtly high lactate, growth may be less efficient 
in those settings and may only be possible in select subclones.  
 
Lactate uptake without hypoxia up-regulates Hif1a and angiogenesis in ASPS 
 Others have shown that lactate can contribute to angiogenesis (Semenza, 2008; 
Sonveaux et al., 2008). In glycolytic glioma tumor cells in vitro, lactate exposure 
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hydroxylation, leading to increased VEGF production (Lowry et al., 1983; Lu et al., 
2005; Lu et al., 2002). Others have shown that oxidative tumor cells in vitro activate 
HIF1α via importation of lactate (De Saedeleer et al., 2012). IP lactate administration in 
mice has enhanced xenografted tumor metastasis and vascularity (Bonuccelli et al., 
2010).  
ASPS has long been known to be highly vascular and to express many 
angiogenic factors, such as HIF1α (Lazar et al., 2007; Vistica et al., 2009). We have 
now added to that observation the confirmation that ASPS is also normoxic. ASPSs 
express high levels of lactate transporters that associate with lactate import (Mct1 and 
Cd147) but not export (Mct4) and have abundant mitochondria. Not only do tumors form 
in areas of high lactate flux both in our model and in humans, but providing exogenous 
lactate also dramatically increased angiogenesis and tumor cell proliferation. Human 
cell lines known to express ASPSCR1-TFE3 proliferated in response to exogenous 
lactate and increased in nuclear HIF1α.  
Several cancer metabolism investigations have emphasized the poor prognostic 
impact of hypoxia and high lactate, but these also typically associate with transitions to 
more metabolically quiescent cellular states (Brizel et al., 2001; Walenta et al., 1997; 
Walenta et al., 2004). This is not so with ASPS, which oxidatively metabolizes lactate 
and increases proliferation in response to exogenous lactate. 
For years, scientists have understood HIF1α to be induced by hypoxia 
(Semenza, 2012). In a similar light, lactate was also long-considered to be elevated only 
in hypoxia. Both paradigms are shifting. There is an abundance of evidence that 
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described by the lactate shuttle (Brooks, 2002). Further, in vitro studies within the last 
year have shown lactate to be a powerful driver of HIF1α induction in normoxic 
conditions (De Saedeleer et al., 2012). We were able to test directly for the first time the 
degree to which increasing lactate in normoxia is an angiogenic signaling molecule 
driving tumorigenesis in vivo. 
To conclude, ASPS is a deadly and rare tumor that portends a poor prognosis. In 
our efforts to characterize this particular tumor and open the door for novel metabolic 
treatments, we have shown that the tumor microenvironment can have dramatic 
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All mouse work was performed with the approval of the institutional animal care and use 
committee and in accordance with international legal and ethical norms. The EWSR1-
ATF1, SS18-SSX2, and LacZ mice were previously described (Haldar et al., 2007; 
Soriano, 1999; Straessler et al., 2013), as were Rosa26-CreER and Prx1-CreERT2 
mice (Badea et al., 2003; Hasson et al., 2007). The full length cDNA of type 2 
ASPSCR1-TFE3 was reverse transcribed from total RNA isolated from a human ASPS. 
The Rosa26-LSL-AT3 targeting vector was electroporated into R1 mouse embryonic 
stem cells, which were selected, screened, and microinjected into blastocysts. Please 
see the Supplemental Experimental Procedures for additional details. 
 
Clinical 
With the approval of the institutional review board and in accordance with all 
international legal and ethical standards, fresh surgical specimens from consenting 
patients were banked and stored, then analyzed after annotation with histopathological, 




Sequencing was performed on an Illumina HiSeq 2000 (Illumina) using a 50 
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OverdispersedRegionScanSeqs script in the USeq package (Nix et al., 2008) calculated 
the expression levels of ENSEMBL genes in FPKM values. USeq also discovers 
differentially expressed genes between two RNA-seq libraries by calling the DESeq R 
package (Anders and Huber, 2010).  
GEO data were normalized by DChip (Li and Hung Wong, 2001). GSEA was 
performed with Broad Institute software (Mootha et al., 2003; Subramanian et al., 2005). 
The Harris hypoxia gene set is curated by the Broad Institute (Harris, 2002), as is 
MitoCarta, including the original 1098 mouse genes, whose proteins localize to the 
mitochondria, and their 1013 human homologues (Pagliarini et al., 2008). Gene 
ontology analysis was performed with GO-Elite software (Zambon et al., 2012). Please 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
Alveolar Soft Part Sarcomagenesis in the Mouse   27 
 
Acknowledgements 
The authors thank L. Bruce Gladden from Auburn University, Maarten W. N. Nijsten 
from University Medical Center Groningen, The Netherlands, and Don Ayer from the 
Department of Oncologic Sciences for helpful conversations regarding lactate 
physiology and metabolism, Marc Ladanyi from Memorial Sloan Kettering Cancer 
Center for provision of human cell lines, Matt Hockin of the Department of Human 
Genetics for provision of the TATCre, Sheryl Tripp from ARUP laboratories for help with 
immunohistochemistry, Shaobo Pei and Sihem Boudina from the metabolic phenotyping 
core facility for help with SeaHorse experiments, Brian Dally from the sequencing core 
facility for help with the RNAseq, and Tim Mosbruger and Brett Milash from the 
bioinformatics core facility for help with the RNAseq analysis. This work was directly 
supported by the Alex’s Lemonade Stand Foundation (K.B.J.) and the Sherman 
Coleman Resident Research Award (M.L.G.). K.B.J. receives additional career 
development support from the Damon Runyon Cancer Research Foundation and 
National Cancer Institute (National Institutes of Health, NIH) K08CA138764. This work 
was also partly supported by P30CA042014 from the National Cancer Institute. The 
content is solely the responsibility of the authors and does not necessarily represent the 





















anuscript          
University of Utah Institutional Repository  
Author Manuscript
Alveolar Soft Part Sarcomagenesis in the Mouse   28 
 
References 
Agaimy, A., Rosch, J., Weyand, M., and Strecker, T. (2012). Primary and metastatic 
cardiac sarcomas: a 12-year experience at a German heart center. Int J Clin Exp Pathol 
5, 928-938. 
Anders, S., and Huber, W. (2010). Differential expression analysis for sequence count 
data. Genome Biol 11, R106. 
Argani, P., Antonescu, C.R., Illei, P.B., Lui, M.Y., Timmons, C.F., Newbury, R., Reuter, 
V.E., Garvin, A.J., Perez-Atayde, A.R., Fletcher, J.A., et al. (2001). Primary renal 
neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive 
tumor entity previously included among renal cell carcinomas of children and 
adolescents. Am J Pathol 159, 179-192. 
Argani, P., Lal, P., Hutchinson, B., Lui, M.Y., Reuter, V.E., and Ladanyi, M. (2003). 
Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a 
sensitive and specific immunohistochemical assay. The American journal of surgical 
pathology 27, 750-761. 
Aubert, A., Costalat, R., Magistretti, P.J., and Pellerin, L. (2005). Brain lactate kinetics: 
Modeling evidence for neuronal lactate uptake upon activation. Proc Natl Acad Sci U S 
A 102, 16448-16453. 
Badea, T.C., Wang, Y., and Nathans, J. (2003). A noninvasive genetic/pharmacologic 
strategy for visualizing cell morphology and clonal relationships in the mouse. J 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
Alveolar Soft Part Sarcomagenesis in the Mouse   29 
 
Bodi, I., Gonzalez, D., Epaliyange, P., Gullan, R., and Fisher, C. (2009). Meningeal 
alveolar soft part sarcoma confirmed by characteristic ASPCR1-TFE3 fusion. 
Neuropathology 29, 460-465. 
Bonuccelli, G., Tsirigos, A., Whitaker-Menezes, D., Pavlides, S., Pestell, R.G., 
Chiavarina, B., Frank, P.G., Flomenberg, N., Howell, A., Martinez-Outschoorn, U.E., et 
al. (2010). Ketones and lactate "fuel" tumor growth and metastasis: Evidence that 
epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9, 3506-3514. 
Brizel, D.M., Schroeder, T., Scher, R.L., Walenta, S., Clough, R.W., Dewhirst, M.W., 
and Mueller-Klieser, W. (2001). Elevated tumor lactate concentrations predict for an 
increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 51, 
349-353. 
Brooks, G.A. (2002). Lactate shuttles in nature. Biochem Soc Trans 30, 258-264. 
Brooks, G.A., and Gaesser, G.A. (1980). End points of lactate and glucose metabolism 
after exhausting exercise. J Appl Physiol Respir Environ Exerc Physiol 49, 1057-1069. 
Burns, P.A., and Wilson, D.J. (2003). Angiogenesis mediated by metabolites is 
dependent on vascular endothelial growth factor (VEGF). Angiogenesis 6, 73-77. 
Covell, D.G., Wallqvist, A., Kenney, S., and Vistica, D.T. (2012). Bioinformatic analysis 
of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
Alveolar Soft Part Sarcomagenesis in the Mouse   30 
 
Das, K.K., Singh, R.K., Jaiswal, S., Agrawal, V., Jaiswal, A.K., and Behari, S. (2012). 
Alveolar soft part sarcoma of the frontal calvarium and adjacent frontal lobe. J Pediatr 
Neurosci 7, 36-39. 
De Saedeleer, C.J., Copetti, T., Porporato, P.E., Verrax, J., Feron, O., and Sonveaux, 
P. (2012). Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human 
tumor cells. PLoS One 7, e46571. 
Folpe, A.L., and Deyrup, A.T. (2006). Alveolar soft-part sarcoma: a review and update. J 
Clin Pathol 59, 1127-1132. 
Fox, B.D., Patel, A., Suki, D., and Rao, G. (2009). Surgical management of metastatic 
sarcoma to the brain. J Neurosurg 110, 181-186. 
Gertz, E.W., Wisneski, J.A., Stanley, W.C., and Neese, R.A. (1988). Myocardial 
substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate 
isotope experiments. The Journal of clinical investigation 82, 2017-2025. 
Gladden, L.B. (2008). A lactatic perspective on metabolism. Med Sci Sports Exerc 40, 
477-485. 
Haldar, M., Hancock, J.D., Coffin, C.M., Lessnick, S.L., and Capecchi, M.R. (2007). A 
conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer 
Cell 11, 375-388. 
Halestrap, A.P. (2013). The SLC16 gene family - structure, role and regulation in health 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
Alveolar Soft Part Sarcomagenesis in the Mouse   31 
 
Harris, A.L. (2002). Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 
2, 38-47. 
Hasson, P., Del Buono, J., and Logan, M.P. (2007). Tbx5 is dispensable for forelimb 
outgrowth. Development 134, 85-92. 
Helman, L.J., and Meltzer, P. (2003). Mechanisms of sarcoma development. Nat Rev 
Cancer 3, 685-694. 
Ishiguro, M., Iwasaki, H., Ohjimi, Y., and Kaneko, Y. (2004). Establishment and 
characterization of a renal cell carcinoma cell line (FU-UR-1) with the reciprocal ASPL-
TFE3 fusion transcript. Oncology reports 11, 1169-1175. 
Joshi, S.K., Hashimoto, K., and Koni, P.A. (2002). Induced DNA recombination by Cre 
recombinase protein transduction. Genesis 33, 48-54. 
Kawanami, A., Matsushita, T., Chan, Y.Y., and Murakami, S. (2009). Mice expressing 
GFP and CreER in osteochondro progenitor cells in the periosteum. Biochem Biophys 
Res Commun 386, 477-482. 
Keller, C., Arenkiel, B.R., Coffin, C.M., El-Bardeesy, N., DePinho, R.A., and Capecchi, 
M.R. (2004). Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity 
of Ink4a/ARF and Trp53 loss of function. Genes Dev 18, 2614-2626. 
Kenney, S., Vistica, D.T., Stockwin, L.H., Burkett, S., Hollingshead, M.G., Borgel, S.D., 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
Alveolar Soft Part Sarcomagenesis in the Mouse   32 
 
manifesting key features of alveolar soft part sarcoma. Journal of pediatric 
hematology/oncology 33, 360-368. 
Kobos, R., Nagai, M., Tsuda, M., Merl, M.Y., Saito, T., Lae, M., Mo, Q., Olshen, A., 
Lianoglou, S., Leslie, C., et al. (2013). Combining integrated genomics and functional 
genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the 
ASPSCR1-TFE3 fusion oncoprotein. The Journal of pathology 229, 743-754. 
Kumar, N., Agarwal, S., Ahuja, A., Das, P., Airon, B., and Ray, R. (2011). Spectrum of 
cardiac tumors excluding myxoma: Experience of a tertiary center with review of the 
literature. Pathol Res Pract 207, 769-774. 
Kumar, V.B., Viji, R.I., Kiran, M.S., and Sudhakaran, P.R. (2007). Endothelial cell 
response to lactate: implication of PAR modification of VEGF. J Cell Physiol 211, 477-
485. 
Kummar, S., Allen, D., Monks, A., Polley, E.C., Hose, C.D., Ivy, S.P., Turkbey, I.B., 
Lawrence, S., Kinders, R.J., Choyke, P., et al. (2013). Cediranib for metastatic alveolar 
soft part sarcoma. J Clin Oncol 31, 2296-2302. 
Ladanyi, M., Antonescu, C.R., Drobnjak, M., Baren, A., Lui, M.Y., Golde, D.W., and 
Cordon-Cardo, C. (2002). The precrystalline cytoplasmic granules of alveolar soft part 
sarcoma contain monocarboxylate transporter 1 and CD147. Am J Pathol 160, 1215-
1221. 
Ladanyi, M., Lui, M.Y., Antonescu, C.R., Krause-Boehm, A., Meindl, A., Argani, P., 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
Alveolar Soft Part Sarcomagenesis in the Mouse   33 
 
der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 
transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20, 48-57. 
Lazar, A.J., Das, P., Tuvin, D., Korchin, B., Zhu, Q., Jin, Z., Warneke, C.L., Zhang, P.S., 
Hernandez, V., Lopez-Terrada, D., et al. (2007). Angiogenesis-promoting gene patterns 
in alveolar soft part sarcoma. Clinical cancer research : an official journal of the 
American Association for Cancer Research 13, 7314-7321. 
Li, C., and Hung Wong, W. (2001). Model-based analysis of oligonucleotide arrays: 
model validation, design issues and standard error application. Genome Biol 2, 
RESEARCH0032. 
Logan, M., Martin, J.F., Nagy, A., Lobe, C., Olson, E.N., and Tabin, C.J. (2002). 
Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl 
enhancer. Genesis 33, 77-80. 
Lowry, O.H., Berger, S.J., Carter, J.G., Chi, M.M., Manchester, J.K., Knor, J., and 
Pusateri, M.E. (1983). Diversity of metabolic patterns in human brain tumors: enzymes 
of energy metabolism and related metabolites and cofactors. J Neurochem 41, 994-
1010. 
Lu, H., Dalgard, C.L., Mohyeldin, A., McFate, T., Tait, A.S., and Verma, A. (2005). 
Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
Alveolar Soft Part Sarcomagenesis in the Mouse   34 
 
Lu, H., Forbes, R.A., and Verma, A. (2002). Hypoxia-inducible factor 1 activation by 
aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277, 
23111-23115. 
Luo, J., Melnick, S., Rossi, A., Burke, R.P., Pfeifer, J.D., and Dehner, L.P. (2008). 
Primary cardiac alveolar soft part sarcoma. A report of the first observed case with 
molecular diagnostics corroboration. Pediatr Dev Pathol 11, 142-147. 
Mao, X., Fujiwara, Y., and Orkin, S.H. (1999). Improved reporter strain for monitoring 
Cre recombinase-mediated DNA excisions in mice. Proc Natl Acad Sci U S A 96, 5037-
5042. 
Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., 
Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E., et al. (2003). PGC-1alpha-
responsive genes involved in oxidative phosphorylation are coordinately downregulated 
in human diabetes. Nat Genet 34, 267-273. 
Nix, D.A., Courdy, S.J., and Boucher, K.M. (2008). Empirical methods for controlling 
false positives and estimating confidence in ChIP-Seq peaks. BMC Bioinformatics 9, 
523. 
Pagliarini, D.J., Calvo, S.E., Chang, B., Sheth, S.A., Vafai, S.B., Ong, S.E., Walford, 
G.A., Sugiana, C., Boneh, A., Chen, W.K., et al. (2008). A mitochondrial protein 
compendium elucidates complex I disease biology. Cell 134, 112-123. 
Perez-Losada, J., Pintado, B., Gutierrez-Adan, A., Flores, T., Banares-Gonzalez, B., del 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
Alveolar Soft Part Sarcomagenesis in the Mouse   35 
 
chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic 
mice. Oncogene 19, 2413-2422. 
Rosenberger, C., Rosen, S., Paliege, A., and Heyman, S.N. (2009). Pimonidazole 
adduct immunohistochemistry in the rat kidney: detection of tissue hypoxia. Methods 
Mol Biol 466, 161-174. 
Semenza, G.L. (2008). Tumor metabolism: cancer cells give and take lactate. The 
Journal of clinical investigation 118, 3835-3837. 
Semenza, G.L. (2012). Hypoxia-inducible factors in physiology and medicine. Cell 148, 
399-408. 
Shimozaki, K., Clemenson, G.D., Jr., and Gage, F.H. (2013). Paired related homeobox 
protein 1 is a regulator of stemness in adult neural stem/progenitor cells. J Neurosci 33, 
4066-4075. 
Smetana, H.F., and Scott, W.F., Jr. (1951). Malignant tumors of nonchromaffin 
paraganglia. Mil Surg 109, 330-349. 
Sonveaux, P., Vegran, F., Schroeder, T., Wergin, M.C., Verrax, J., Rabbani, Z.N., De 
Saedeleer, C.J., Kennedy, K.M., Diepart, C., Jordan, B.F., et al. (2008). Targeting 
lactate-fueled respiration selectively kills hypoxic tumor cells in mice. The Journal of 
clinical investigation 118, 3930-3942. 
Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
Alveolar Soft Part Sarcomagenesis in the Mouse   36 
 
Stanley, W.C. (1991). Myocardial lactate metabolism during exercise. Med Sci Sports 
Exerc 23, 920-924. 
Stockwin, L.H., Vistica, D.T., Kenney, S., Schrump, D.S., Butcher, D.O., Raffeld, M., 
and Shoemaker, R.H. (2009). Gene expression profiling of alveolar soft-part sarcoma 
(ASPS). BMC cancer 9, 22. 
Straessler, K.M., Jones, K.B., Hu, H., Jin, H., van de Rijn, M., and Capecchi, M.R. 
(2013). Modeling clear cell sarcomagenesis in the mouse: cell of origin differentiation 
state impacts tumor characteristics. Cancer Cell 23, 215-227. 
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., 
Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set 
enrichment analysis: a knowledge-based approach for interpreting genome-wide 
expression profiles. Proc Natl Acad Sci U S A 102, 15545-15550. 
Vistica, D.T., Hollingshead, M., Borgel, S.D., Kenney, S., Stockwin, L.H., Raffeld, M., 
Schrump, D.S., Burkett, S., Stone, G., Butcher, D.O., et al. (2009). Therapeutic 
vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic 
therapy. Journal of pediatric hematology/oncology 31, 561-570. 
Walenta, S., Salameh, A., Lyng, H., Evensen, J.F., Mitze, M., Rofstad, E.K., and 
Mueller-Klieser, W. (1997). Correlation of high lactate levels in head and neck tumors 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
Alveolar Soft Part Sarcomagenesis in the Mouse   37 
 
Walenta, S., Schroeder, T., and Mueller-Klieser, W. (2004). Lactate in solid malignant 
tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem 
11, 2195-2204. 
Xiong, M., Elson, G., Legarda, D., and Leibovich, S.J. (1998). Production of vascular 
endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and 
the inducible nitric oxide synthase pathway. Am J Pathol 153, 587-598. 
Zambon, A.C., Gaj, S., Ho, I., Hanspers, K., Vranizan, K., Evelo, C.T., Conklin, B.R., 
Pico, A.R., and Salomonis, N. (2012). GO-Elite: a flexible solution for pathway and 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
Alveolar Soft Part Sarcomagenesis in the Mouse   38 
 
Figure Legends 
Figure 1. A mouse allele with conditional expression of human ASPSCR1-TFE3. 
(A) Schematic demonstrating generation of the fusion transcript in human alveolar soft 
part sarcoma, which was reverse transcribed to a complementary DNA (cDNA) and 
targeted to the Rosa26 locus, separated from its promoter by a loxP-flanked stop 
sequence consisting of the neomycin resistance gene (neoR) and a poly-adenylation 
transcription termination sequence. The cDNA is followed by enhanced green 
fluorescent protein (eGFP) and internal ribosomal entry site (IRES), such that both the 
fusion gene and eGFP will be translated from the same transcript following Cre-
mediated recombination to remove the stop. (B) Photomicrographs of embryonic day 
12.5 Rosa26LSL-AT3/wt fibroblasts 48 hours after exposure to TATCre or control, 
demonstrating GFP fluorescence from the recombined allele and (C) reverse 
transcriptase polymerase chain reaction (RT-PCR) showing presence of the fusion gene 
transcript following TATCre, but not control. 
 
Figure 2. ASPSCR1-TFE3 induces rapid tumorigenesis, restricted to the cranium. 
(A) Chart depicting the relative rates of tumorigenesis and (B) diagrams of the anatomic 
distribution of tumors among Rosa26-LSL-EWSR1-ATF1/CreER, Rosa26-
LSL-SS18-SSX2/CreER, and 
Rosa26-LSL-AT3/CreER mice. Lateral cranium radiographs (C-D), gross dissection mid-
sagittal brain photos (E-F), and GFP fluorescence photos (G-H) of 3 month old Rosa26-
LSL-AT3/CreER (C, E, G) and Rosa26-
LSL-AT3/wt (D, F, H) mice showing occipital expansion 
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and G) and demonstrates GFP fluorescence from the active AT3 allele. Representative 
photomicrographs of the gamut of intra-cranial tumor presentations in Rosa26-LSL-
AT3/CreER mice, in which most were intra-parenchymal (I), but one encroached on the 
choroid plexus (J) and another developed within the eye (K). 
 
Figure 3. ASPSCR1-TFE3-induced mouse tumors recapitulate human alveolar soft 
part sarcoma diagnostic histopathology. 
(A) Low- and (B) high-power hematoxylin and eosin photomicrographs from tumors 
arising in Rosa26-LSL-AT3/CreER mice match those from human ASPSs (C and D) in the 
overall tissue architecture of loosely nesting cells between arcading capillary networks 
and cellular features of round large nuclei with prominent nucleoli. (E) Photomicrograph 
of diastase-resistant periodic acid Schiff staining identifies the pathognomonic 
cytoplasmic granules (black arrows) in Rosa26-LSL-AT3/CreER mouse tumors and human 
ASPSs (F). Clinical immunohistochemistry against human TFE3 demonstrates strong 
nuclear staining in both Rosa26-LSL-AT3/CreER mouse tumors (G) and human ASPSs (H). 
H&E photomicrographs demonstrate a tumor growing between sulci near the investing 
pia mater (arrows in I), which was sometimes maintained between the tumor cells and 
the surrounding tissues (arrows in J); other invading tumor cells into the cerebellum (K), 
cerebral cortex (L), and choroid plexus (M) maintained no intervening leptomeningeal 
layer, but often associated closely with small vessels (arrows in N). (All scale bars and 
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Figure 4. ASPSCR1-TFE3-induced mouse tumors recapitulate human alveolar soft 
part sarcoma by transcriptome profile. 
(A) Series of Broad Institute gene set enrichment analysis (GSEA) plots testing the 500 
most significantly up-regulated (left, in each pair) and down-regulated (right, in each 
pair) genes from the Rosa26-LSL-AT3/CreER mouse tumor (mASPS) to muscle RNAseq 
comparison, the human alveolar soft part sarcoma (hASPS) to muscle RNAseq 
comparison, and the human ASPS to muscle microarray comparison (GEO), in each of 
the other data sets. All of the up-regulated gene lists had high normalized enrichment 
scores (NES) and were statistically significant with false discover rate q-values less than 
0.0005. None of the down-regulated gene lists showed enrichment. (B) Heat map of 
log2 transformed fold-changes from the control mean of the 539 genes with at least 2-
fold and significant mean up-regulation in all three data sets. (C) Chart of the Z-scores 
of the most significant biological process gene ontologies from GO-Elite analysis of the 
539 genes up-regulated in all three data sets. 
 
Figure 5. ASPSCR1-TFE3-induced tumorigenesis is most efficient within the 
cranium. 
(A) Diagram depicting the relative incidence and representative histopathology of the 
two grouped anatomic locations of tumors arising Prx1-CreERT2;Rosa26-LSL-AT3/wt mice 
after receiving tamoxifen at age 2 weeks, intra-cranial periosteum and in the brain 
parenchyma, but not in the extra-cranial periosteum or the limb. (B) Photomicrographs 
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proximal humerus in 3 week old Prx1-CreERT2;Rosa26-LacZ/wt mice after receiving 
tamoxifen at age 2 weeks, demonstrating the Prx1-CreERT2 lineage in each location 
(blue cells identified by black arrows), only the first of which led to identifiable 
tumorigenesis when initiating the AT3 allele. (Scale bars in A and panel widths in B are 
each 100µm in length.) 
 
Figure 6. ASPSCR1-TFE3-induced mouse tumor lactate transport gene 
expression and tissue lactate levels in the mouse. 
(A) Chart of the gene expression by fragments per kilobase of exon per million 
fragments mapped (FPKM) in Rosa26-LSL-AT3/CreER mouse tumors (red) and muscle 
samples (black), showing high and significantly up-regulated expression of both Cd147 
and Mct1 in tumors and low and significantly down-regulated expression of Mct4. (B) 
Plot of the individual (dots) and mean (bars) concentrations of lactate in the tissues of 5 
mice, determined biochemically.  
 
Figure 7. ASPSCR1-TFE3-induced mouse tumors and human alveolar soft part 
sarcomas can metabolize lactate. 
Heat maps from Rosa26-LSL-AT3/CreER mouse tumors (A) and human alveolar soft part 
sarcomas (B) showing the log2 ratios of expression normalized to the mean for the 
Broad Institute’s curated MitoCarta gene list. (C) Chart of the mean ± standard deviation 
of the oxygen consumption rate (normalized by DNA content) of tissue sections from 
tumors arising in mice induced by each of three fusion oncogenes, representing alveolar 
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of the mean ± standard deviation of the percent change in oxygen consumption among 
fresh tissue section from three mouse tumor types upon administration of 10mM lactate 
substrate (n = 5 for each). 
 
Figure 8. ASPSCR1-TFE3-induced mouse tumors express hypoxia genes in the 
absence of hypoxia and respond to exogenous lactate. 
(A) Explanatory diagram of the pathway by which either hypoxia or imported lactate can 
decrease 2-oxoglutarate-mediated Hif1α hydroxylation and degradation (Lu et al., 2002) 
(Lu et al., 2005). (B) Photomicrographs of pimonidazole-treated Rosa26-LSL-AT3/CreER 
mouse tumor and kidney tissue sections stained with immunohistochemistry against 
pimonidazole adducts (above; brown depicts presence of hypoxia) and Hif1α (below), 
demonstrating nuclear Hif1α, but no hypoxia in tumors, and Hif1α correlating to hypoxia 
in normal renal tubules.  (C) Broad Institute gene set enrichment analysis for the 
established Harris hypoxia gene list in the Rosa26-LSL-AT3/CreER mouse tumor (mASPS) 
to muscle RNAseq comparison, showing upregulation of many ostensibly hypoxia-
driven genes in the tumors. (Scale bars are 10µm in length.) (D) Representative 
photomicrographs of immunohistochemistry against Ki-67, indicating proliferating nuclei 
(brown) or Cd31, indicating vascular endothelial cells (brown) after 2 weeks of lactate or 
saline administration to Rosa26-LSL-AT3/CreER mice bearing tumors. (E) Chart of the mean 
± standard deviation of the ratio of Ki-67-positive tumor cell nuclei to total tumor cell 
nuclei between the two groups (n = 5 lactate and 7 saline controls). (F) Chart of the 
mean ± standard deviation of the ratio of the linear vessel perimeter to total tumor cell 
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presenting mean ± standard deviation of the relative viability of ASPSCR1-TFE3-
expressing human cancer cell lines FU-UR-1 (at 48 hours) and ASPS-1 (at 72 hours) in 
increasing concentrations of sodium lactate (n = 3 for each point; experiments also 
repeated). (I) Western blots showing increased nuclear HIF1α when exposed to 20mM 
sodium lactate that is blocked by the MCT1-inhibitor, CHC at 0.1mM in FU-UR-1 cells 
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Supplemental Table 1. Genes 2-fold and significantly up-regulated in mouse and both human data 
sets comparing ASPSCR1-TFE3-driven tumors to skeletal muscle controls. 
    
Human ENSEMBL# Probe on HU133+2.0 Human Gene Symbol Mouse Gene Symbol 
    
ENSG00000001036 223120_at FUCA2 Fuca2 
ENSG00000002933 218345_at TMEM176A Tmem176a 
ENSG00000004864 229061_s_at SLC25A13 Slc25a13 
ENSG00000005022 200657_at SLC25A5 Slc25a5 
ENSG00000005893 203041_s_at LAMP2 Lamp2 
ENSG00000006075 205114_s_at CCL3 Ccl3 
ENSG00000006118 218834_s_at TMEM132A Tmem132a 
ENSG00000006634 204244_s_at DBF4 Dbf4 
ENSG00000007372 235795_at PAX6 Pax6 
ENSG00000008394 1565162_s_at MGST1 Mgst1 
ENSG00000011304 212016_s_at PTBP1 Ptbp1 
ENSG00000011426 1552619_a_at ANLN Anln 
ENSG00000012124 38521_at CD22 Cd22 
ENSG00000013288 214703_s_at MAN2B2 Man2b2 
ENSG00000013306 223649_s_at SLC25A39 Slc25a39 
ENSG00000019505 226086_at SYT13 Syt13 
ENSG00000019549 213139_at SNAI2 Snai2 
ENSG00000023171 212906_at GRAMD1B Gramd1b 
ENSG00000024526 222958_s_at DEPDC1 Depdc1a 
ENSG00000030582 211284_s_at GRN Grn 
ENSG00000035499 226980_at DEPDC1B Depdc1b 
ENSG00000035862 203167_at TIMP2 Timp2 
ENSG00000039560 202052_s_at RAI14 Rai14 
ENSG00000041515 1557720_s_at MYO16 Myo16 
ENSG00000043462 205269_at LCP2 Lcp2 
ENSG00000049860 201944_at HEXB Hexb 
ENSG00000050165 214247_s_at DKK3 Dkk3 
ENSG00000052795 225924_at FNIP2 Fnip2 
ENSG00000054690 225726_s_at PLEKHH1 Plekhh1 
ENSG00000055732 220484_at MCOLN3 Mcoln3 
ENSG00000057019 224911_s_at DCBLD2 Dcbld2 
ENSG00000057252 228479_at SOAT1 Soat1 
ENSG00000059573 222416_at ALDH18A1 Aldh18a1 
ENSG00000060709 214811_at RIMBP2 Rimbp2 
ENSG00000060982 226517_at BCAT1 Bcat1 
ENSG00000064666 201605_x_at CNN2 Cnn2 
ENSG00000066279 219918_s_at ASPM Aspm 
ENSG00000066322 218028_at ELOVL1 Elovl1 
ENSG00000066468 208229_at FGFR2 Fgfr2 
ENSG00000067057 201037_at PFKP Pfkp 
ENSG00000067167 201398_s_at TRAM1 Tram1 
Supplemental Text & Figures
Click here to download Supplemental Text & Figures: SupplementalInformation.pdf 
Human ENSEMBL#        Probe on HU133+2.0  Human Gene Symbol Mouse Gene Symbol 
 
ENSG00000069424 203402_at KCNAB2 Kcnab2 
ENSG00000069849 208836_at ATP1B3 Atp1b3 
ENSG00000069966 204000_at GNB5 Gnb5 
ENSG00000069974 209515_s_at RAB27A Rab27a 
ENSG00000070669 205047_s_at ASNS Asns 
ENSG00000072041 232263_at SLC6A15 Slc6a15 
ENSG00000072110 208637_x_at ACTN1 Actn1 
ENSG00000072571 207165_at HMMR Hmmr 
ENSG00000074696 222404_x_at PTPLAD1 Ptplad1 
ENSG00000074800 201231_s_at ENO1 Eno1 
ENSG00000075618 210933_s_at FSCN1 Fscn1 
ENSG00000075624 AFFX-HSAC07/X00351_M_at ACTB Actb 
ENSG00000076944 209367_at STXBP2 Stxbp2 
ENSG00000077585 204137_at GPR137B Gpr137b 
ENSG00000080824 211969_at HSP90AA1 Hsp90aa1 
ENSG00000080986 204162_at NDC80 Ndc80 
ENSG00000081087 218196_at OSTM1 Ostm1 
ENSG00000081803 219572_at CADPS2 Cadps2 
ENSG00000083720 202780_at OXCT1 Oxct1 
ENSG00000083857 201579_at FAT1 Fat1 
ENSG00000085733 201059_at CTTN Cttn 
ENSG00000087077 209129_at TRIP6 Trip6 
ENSG00000087088 211833_s_at BAX Bax 
ENSG00000087253 239598_s_at LPCAT2 Lpcat2 
ENSG00000087448 225732_at KLHDC5 Klhl42 
ENSG00000088367 212336_at EPB41L1 Epb4.1l1 
ENSG00000090889 218355_at KIF4A Kif4 
ENSG00000091129 204105_s_at NRCAM Nrcam 
ENSG00000091428 205651_x_at RAPGEF4 Rapgef4 
ENSG00000091651 219105_x_at ORC6 Orc6 
ENSG00000091879 237261_at ANGPT2 Angpt2 
ENSG00000092445 211431_s_at TYRO3 Tyro3 
ENSG00000092820 208623_s_at EZR Ezr 
ENSG00000092853 243840_at CLSPN Clspn 
ENSG00000094804 203968_s_at CDC6 Cdc6 
ENSG00000095383 222173_s_at TBC1D2 Tbc1d2 
ENSG00000095397 221887_s_at DFNB31 Whrn 
ENSG00000097046 204510_at CDC7 Cdc7 
ENSG00000099194 223839_s_at SCD Scd2 
ENSG00000099377 222817_at HSD3B7 Hsd3b7 
ENSG00000100075 210010_s_at SLC25A1 Slc25a1 
ENSG00000100167 223362_s_at 41520 3-Sep 
ENSG00000100292 203665_at HMOX1 Hmox1 
ENSG00000100297 201755_at MCM5 Mcm5 
ENSG00000100299 204443_at ARSA Arsa 
ENSG00000100526 1555758_a_at CDKN3 Cdkn3 
Human ENSEMBL#        Probe on HU133+2.0  Human Gene Symbol Mouse Gene Symbol 
 
ENSG00000100644 200989_at HIF1A Hif1a 
ENSG00000100889 202847_at PCK2 Pck2 
ENSG00000100979 202075_s_at PLTP Pltp 
ENSG00000100994 201481_s_at PYGB Pygb 
ENSG00000100997 224742_at ABHD12 Abhd12 
ENSG00000101160 210042_s_at CTSZ Ctsz 
ENSG00000101224 201853_s_at CDC25B Cdc25b 
ENSG00000101255 218145_at TRIB3 Trib3 
ENSG00000101349 210721_s_at PAK7 Pak7 
ENSG00000101350 225205_at KIF3B Kif3b 
ENSG00000101412 2028_s_at E2F1 E2f1 
ENSG00000101577 202459_s_at LPIN2 Lpin2 
ENSG00000101680 227048_at LAMA1 Lama1 
ENSG00000101773 203344_s_at RBBP8 Rbbp8 
ENSG00000101850 206696_at GPR143 Gpr143 
ENSG00000101856 201121_s_at PGRMC1 Pgrmc1 
ENSG00000101911 230352_at PRPS2 Prps2 
ENSG00000102032 206617_s_at RENBP Renbp 
ENSG00000102096 204269_at PIM2 Pim2 
ENSG00000102221 204866_at PHF16 Phf16 
ENSG00000102265 201666_at TIMP1 Timp1 
ENSG00000102393 214430_at GLA Gla 
ENSG00000103034 209159_s_at NDRG4 Ndrg4 
ENSG00000103249 38069_at CLCN7 Clcn7 
ENSG00000103257 201195_s_at SLC7A5 Slc7a5 
ENSG00000103855 224859_at CD276 Cd276 
ENSG00000103888 212942_s_at KIAA1199 9930013L23Rik 
ENSG00000104093 212820_at DMXL2 Dmxl2 
ENSG00000104361 220128_s_at NIPAL2 Nipal2 
ENSG00000104490 211685_s_at NCALD Ncald 
ENSG00000104549 209218_at SQLE Sqle 
ENSG00000104723 209228_x_at TUSC3 Tusc3 
ENSG00000105011 218115_at ASF1B Asf1b 
ENSG00000105223 201050_at PLD3 Pld3 
ENSG00000105402 206491_s_at NAPA Napa 
ENSG00000105486 202726_at LIG1 Lig1 
ENSG00000105699 208190_s_at LSR Lsr 
ENSG00000105939 225634_at ZC3HAV1 Zc3hav1 
ENSG00000106266 228231_at SNX8 Snx8 
ENSG00000106565 220532_s_at TMEM176B Tmem176b 
ENSG00000106617 222582_at PRKAG2 Prkag2 
ENSG00000106624 201792_at AEBP1 Aebp1 
ENSG00000106772 212805_at PRUNE2 Prune2 
ENSG00000107249 230258_at GLIS3 Glis3 
ENSG00000107521 217354_s_at HPS1 Hps1 
ENSG00000107731 226899_at UNC5B Unc5b 
Human ENSEMBL#        Probe on HU133+2.0  Human Gene Symbol Mouse Gene Symbol 
 
ENSG00000108375 218704_at RNF43 Rnf43 
ENSG00000108784 204360_s_at NAGLU Naglu 
ENSG00000108828 208626_s_at VAT1 Vat1 
ENSG00000109062 201349_at SLC9A3R1 Slc9a3r1 
ENSG00000109103 203271_s_at UNC119 Unc119 
ENSG00000109265 227230_s_at KIAA1211 C530008M17Rik 
ENSG00000109323 203778_at MANBA Manba 
ENSG00000109436 212960_at TBC1D9 Tbc1d9 
ENSG00000109654 202341_s_at TRIM2 Trim2 
ENSG00000109805 218662_s_at NCAPG Ncapg 
ENSG00000109819 219195_at PPARGC1A Ppargc1a 
ENSG00000109854 209448_at HTATIP2 Htatip2 
ENSG00000110090 203633_at CPT1A Cpt1a 
ENSG00000110092 208711_s_at CCND1 Ccnd1 
ENSG00000110492 209035_at MDK Mdk 
ENSG00000110880 221676_s_at CORO1C Coro1c 
ENSG00000111110 212686_at PPM1H Ppm1h 
ENSG00000111206 202580_x_at FOXM1 Foxm1 
ENSG00000111229 208736_at ARPC3 Arpc3 
ENSG00000111412 222767_s_at C12orf49 2410131K14Rik 
ENSG00000111432 219764_at FZD10 Fzd10 
ENSG00000111602 203046_s_at TIMELESS Timeless 
ENSG00000111670 240106_at GNPTAB Gnptab 
ENSG00000111674 201313_at ENO2 Eno2 
ENSG00000111816 207178_s_at FRK Frk 
ENSG00000112379 231856_at KIAA1244 D10Bwg1379e 
ENSG00000112742 204822_at TTK Ttk 
ENSG00000112799 205859_at LY86 Ly86 
ENSG00000112977 201095_at DAP Dap 
ENSG00000112984 218755_at KIF20A Kif20a 
ENSG00000113361 205532_s_at CDH6 Cdh6 
ENSG00000113552 202382_s_at GNPDA1 Gnpda1 
ENSG00000113732 200096_s_at ATP6V0E1 Atp6v0e 
ENSG00000113805 229831_at CNTN3 Cntn3 
ENSG00000113810 201663_s_at SMC4 Smc4 
ENSG00000114346 234992_x_at ECT2 Ect2 
ENSG00000114573 201972_at ATP6V1A Atp6v1a 
ENSG00000114757 241833_at PEX5L Pex5l 
ENSG00000115738 201565_s_at ID2 Id2 
ENSG00000115884 201287_s_at SDC1 Sdc1 
ENSG00000116675 204720_s_at DNAJC6 Dnajc6 
ENSG00000116954 218088_s_at RRAGC Rragc 
ENSG00000116991 233587_s_at SIPA1L2 Sipa1l2 
ENSG00000117322 205544_s_at CR2 Cr2 
ENSG00000117394 201250_s_at SLC2A1 Slc2a1 
ENSG00000117410 200078_s_at ATP6V0B Atp6v0b 
Human ENSEMBL#        Probe on HU133+2.0  Human Gene Symbol Mouse Gene Symbol 
 
ENSG00000117519 201445_at CNN3 Cnn3 
ENSG00000117643 218918_at MAN1C1 Man1c1 
ENSG00000117724 209172_s_at CENPF Cenpf 
ENSG00000117984 200766_at CTSD Ctsd 
ENSG00000118160 215267_s_at SLC8A2 Slc8a2 
ENSG00000118193 236641_at KIF14 Kif14 
ENSG00000118242 219648_at MREG Mreg 
ENSG00000118508 204214_s_at RAB32 Rab32 
ENSG00000118596 207057_at SLC16A7 Slc16a7 
ENSG00000118785 209875_s_at SPP1 Spp1 
ENSG00000118855 218109_s_at MFSD1 Mfsd1 
ENSG00000118946 205656_at PCDH17 Pcdh17 
ENSG00000119408 223158_s_at NEK6 Nek6 
ENSG00000119537 202419_at KDSR Kdsr 
ENSG00000119655 200701_at NPC2 Npc2 
ENSG00000119943 228384_s_at PYROXD2 Pyroxd2 
ENSG00000119969 223556_at HELLS Hells 
ENSG00000120256 225060_at LRP11 Lrp11 
ENSG00000120539 228468_at MASTL Mastl 
ENSG00000120742 200971_s_at SERP1 Serp1 
ENSG00000120875 226034_at DUSP4 Dusp4 
ENSG00000121064 218217_at SCPEP1 Scpep1 
ENSG00000121068 40560_at TBX2 Tbx2 
ENSG00000121966 209201_x_at CXCR4 Cxcr4 
ENSG00000123095 221530_s_at BHLHE41 Bhlhe41 
ENSG00000123131 201923_at PRDX4 Prdx4 
ENSG00000123219 222848_at CENPK Cenpk 
ENSG00000123416 212639_x_at TUBA1B Tuba1b 
ENSG00000123453 207889_at SARDH Sardh 
ENSG00000123500 217428_s_at COL10A1 Col10a1 
ENSG00000123572 232771_at NRK Nrk 
ENSG00000123836 238450_at PFKFB2 Pfkfb2 
ENSG00000123975 204170_s_at CKS2 Cks2 
ENSG00000123989 202175_at CHPF Chpf 
ENSG00000124126 224909_s_at PREX1 Prex1 
ENSG00000124191 228737_at TOX2 Tox2 
ENSG00000124357 218231_at NAGK Nagk 
ENSG00000124766 201417_at SOX4 Sox4 
ENSG00000124785 218625_at NRN1 Nrn1 
ENSG00000125249 214487_s_at RAP2A Rap2a 
ENSG00000125633 219774_at CCDC93 Ccdc93 
ENSG00000126217 239636_at MCF2L Mcf2l 
ENSG00000126787 203764_at DLGAP5 Dlgap5 
ENSG00000128245 201020_at YWHAH Ywhah 
ENSG00000128656 212624_s_at CHN1 Chn1 
ENSG00000128973 1567080_s_at CLN6 Cln6 
Human ENSEMBL#        Probe on HU133+2.0  Human Gene Symbol Mouse Gene Symbol 
 
ENSG00000129925 221882_s_at TMEM8A Tmem8 
ENSG00000130066 210592_s_at SAT1 Sat1 
ENSG00000130202 225418_at PVRL2 Pvrl2 
ENSG00000130203 212884_x_at APOE Apoe 
ENSG00000130402 200601_at ACTN4 Actn4 
ENSG00000130513 229868_s_at GDF15 Gdf15 
ENSG00000130540 219425_at SULT4A1 Sult4a1 
ENSG00000130813 218429_s_at C19orf66 A230050P20Rik 
ENSG00000130816 201697_s_at DNMT1 Dnmt1 
ENSG00000131171 201311_s_at SH3BGRL Sh3bgrl 
ENSG00000131236 213798_s_at CAP1 Cap1 
ENSG00000131711 214577_at MAP1B Map1b 
ENSG00000131747 201292_at TOP2A Top2a 
ENSG00000131910 206410_at NR0B2 Nr0b2 
ENSG00000132646 201202_at PCNA Pcna 
ENSG00000132718 209198_s_at SYT11 Syt11 
ENSG00000133639 200920_s_at BTG1 Btg1 
ENSG00000134287 200011_s_at ARF3 Arf3 
ENSG00000134504 226246_at KCTD1 Kctd1 
ENSG00000135119 221908_at RNFT2 Rnft2 
ENSG00000135124 204088_at P2RX4 P2rx4 
ENSG00000135127 228320_x_at CCDC64 Ccdc64 
ENSG00000135269 202720_at TES Tes 
ENSG00000135362 1555486_a_at PRR5L Prr5l 
ENSG00000135404 200663_at CD63 Cd63 
ENSG00000135446 202246_s_at CDK4 Cdk4 
ENSG00000135506 200714_x_at OS9 Os9 
ENSG00000135596 218376_s_at MICAL1 Mical1 
ENSG00000135677 212334_at GNS Gns 
ENSG00000135905 219279_at DOCK10 Dock10 
ENSG00000136059 209950_s_at VILL Vill 
ENSG00000136193 201462_at SCRN1 Scrn1 
ENSG00000136205 217853_at TNS3 Tns3 
ENSG00000136235 201141_at GPNMB Gpnmb 
ENSG00000136492 221703_at BRIP1 Brip1 
ENSG00000136830 223019_at FAM129B Fam129b 
ENSG00000136868 203971_at SLC31A1 Slc31a1 
ENSG00000137267 204141_at TUBB2A Tubb2a 
ENSG00000137269 218816_at LRRC1 Lrrc1 
ENSG00000137285 214023_x_at TUBB2B Tubb2b 
ENSG00000137462 204924_at TLR2 Tlr2 
ENSG00000137501 232914_s_at SYTL2 Sytl2 
ENSG00000137672 217287_s_at TRPC6 Trpc6 
ENSG00000137752 211366_x_at CASP1 Casp1 
ENSG00000137807 204709_s_at KIF23 Kif23 
ENSG00000137812 1552680_a_at CASC5 Casc5 
Human ENSEMBL#        Probe on HU133+2.0  Human Gene Symbol Mouse Gene Symbol 
 
ENSG00000138166 209457_at DUSP5 Dusp5 
ENSG00000138180 218542_at CEP55 Cep55 
ENSG00000138311 206448_at ZNF365 Zfp365 
ENSG00000138316 230167_at ADAMTS14 Adamts14 
ENSG00000138650 228635_at PCDH10 Pcdh10 
ENSG00000138670 1554999_at RASGEF1B Rasgef1b 
ENSG00000138778 205046_at CENPE Cenpe 
ENSG00000138821 209267_s_at SLC39A8 Slc39a8 
ENSG00000139146 223038_s_at FAM60A Fam60a 
ENSG00000139354 238756_at GAS2L3 Gas2l3 
ENSG00000139370 225043_at SLC15A4 Slc15a4 
ENSG00000139410 228274_at SDSL Sdsl 
ENSG00000139514 212295_s_at SLC7A1 Slc7a1 
ENSG00000139734 229097_at DIAPH3 Diap3 
ENSG00000140030 214467_at GPR65 Gpr65 
ENSG00000140525 213007_at FANCI Fanci 
ENSG00000140526 63825_at ABHD2 Abhd2 
ENSG00000140853 226474_at NLRC5 Nlrc5 
ENSG00000140859 209661_at KIFC3 Kifc3 
ENSG00000140937 207172_s_at CDH11 Cdh11 
ENSG00000141012 206335_at GALNS Galns 
ENSG00000141682 204285_s_at PMAIP1 Pmaip1 
ENSG00000141959 201102_s_at PFKL Pfkl 
ENSG00000142178 208078_s_at SIK1 Sik1 
ENSG00000142230 1555618_s_at SAE1 Sae1 
ENSG00000142634 222483_at EFHD2 Efhd2 
ENSG00000142731 204886_at PLK4 Plk4 
ENSG00000143036 228221_at SLC44A3 Slc44a3 
ENSG00000143476 218585_s_at DTL Dtl 
ENSG00000143479 210151_s_at DYRK3 Dyrk3 
ENSG00000144057 1555123_at ST6GAL2 St6gal2 
ENSG00000144136 201920_at SLC20A1 Slc20a1 
ENSG00000144369 227370_at FAM171B Fam171b 
ENSG00000144554 242560_at FANCD2 Fancd2 
ENSG00000144567 222129_at FAM134A Fam134a 
ENSG00000145050 202655_at MANF Manf 
ENSG00000145386 213226_at CCNA2 Ccna2 
ENSG00000145476 226745_at CYP4V2 Cyp4v3 
ENSG00000145569 219694_at FAM105A Fam105a 
ENSG00000145685 212658_at LHFPL2 Lhfpl2 
ENSG00000146038 222925_at DCDC2 Dcdc2a 
ENSG00000146267 232067_at C6orf168 Faxc 
ENSG00000146386 223361_at C6orf115 Abracl 
ENSG00000146674 210095_s_at IGFBP3 Igfbp3 
ENSG00000146950 204967_at SHROOM2 Shroom2 
ENSG00000147036 243856_at LANCL3 Lancl3 
Human ENSEMBL#        Probe on HU133+2.0  Human Gene Symbol Mouse Gene Symbol 
 
ENSG00000147416 201089_at ATP6V1B2 Atp6v1b2 
ENSG00000147509 210138_at RGS20 Rgs20 
ENSG00000147606 1552826_at SLC26A7 Slc26a7 
ENSG00000148154 224967_at UGCG Ugcg 
ENSG00000148158 226249_at SNX30 Snx30 
ENSG00000148841 225582_at ITPRIP Itprip 
ENSG00000148848 202952_s_at ADAM12 Adam12 
ENSG00000148926 202912_at ADM Adm 
ENSG00000149483 223113_at TMEM138 Tmem138 
ENSG00000149485 208962_s_at FADS1 Fads1 
ENSG00000149554 205393_s_at CHEK1 Chek1 
ENSG00000149573 203780_at MPZL2 Mpzl2 
ENSG00000150510 230067_at FAM124A Fam124a 
ENSG00000151239 201745_at TWF1 Twf1 
ENSG00000151491 202609_at EPS8 Eps8 
ENSG00000151725 218883_s_at MLF1IP Mlf1ip 
ENSG00000152056 1555731_a_at AP1S3 Ap1s3 
ENSG00000153485 213246_at C14orf109 Tmem251 
ENSG00000153814 225800_at JAZF1 Jazf1 
ENSG00000154917 210127_at RAB6B Rab6b 
ENSG00000155097 202874_s_at ATP6V1C1 Atp6v1c1 
ENSG00000155158 232000_at TTC39B Ttc39b 
ENSG00000155307 220330_s_at SAMSN1 Samsn1 
ENSG00000155368 209389_x_at DBI Dbi 
ENSG00000155886 229110_at SLC24A2 Slc24a2 
ENSG00000155897 206811_at ADCY8 Adcy8 
ENSG00000156802 235266_at ATAD2 Atad2 
ENSG00000156970 203755_at BUB1B Bub1b 
ENSG00000157193 205282_at LRP8 Lrp8 
ENSG00000157456 202705_at CCNB2 Ccnb2 
ENSG00000157470 227756_at FAM81A Fam81a 
ENSG00000157680 206806_at DGKI Dgki 
ENSG00000158769 221664_s_at F11R F11r 
ENSG00000158869 204232_at FCER1G Fcer1g 
ENSG00000159167 204595_s_at STC1 Stc1 
ENSG00000159399 202934_at HK2 Hk2 
ENSG00000159842 212895_s_at ABR Abr 
ENSG00000160271 209050_s_at RALGDS Ralgds 
ENSG00000160714 217978_s_at UBE2Q1 Ube2q1 
ENSG00000161921 223454_at CXCL16 Cxcl16 
ENSG00000162066 219082_at AMDHD2 Amdhd2 
ENSG00000162341 229251_s_at TPCN2 Tpcn2 
ENSG00000162511 201721_s_at LAPTM5 Laptm5 
ENSG00000162704 211963_s_at ARPC5 Arpc5 
ENSG00000162772 1554420_at ATF3 Atf3 
ENSG00000162777 221081_s_at DENND2D Dennd2d 
Human ENSEMBL#        Probe on HU133+2.0  Human Gene Symbol Mouse Gene Symbol 
 
ENSG00000163449 228981_at TMEM169 Tmem169 
ENSG00000163577 235296_at EIF5A2 Eif5a2 
ENSG00000163624 205709_s_at CDS1 Cds1 
ENSG00000163683 224990_at C4orf34 Smim14 
ENSG00000163686 45288_at ABHD6 Abhd6 
ENSG00000163694 218035_s_at RBM47 Rbm47 
ENSG00000163931 208700_s_at TKT Tkt 
ENSG00000164054 222986_s_at SHISA5 Shisa5 
ENSG00000164124 228624_at TMEM144 Tmem144 
ENSG00000164181 227180_at ELOVL7 Elovl7 
ENSG00000164283 208394_x_at ESM1 Esm1 
ENSG00000164484 234994_at TMEM200A Tmem200a 
ENSG00000164604 219898_at GPR85 Gpr85 
ENSG00000164713 223376_s_at BRI3 Bri3 
ENSG00000164733 200839_s_at CTSB Ctsb 
ENSG00000164746 1557636_a_at C7orf57 Gm11992 
ENSG00000164877 219332_at MICALL2 Micall2 
ENSG00000164929 222780_s_at BAALC Baalc 
ENSG00000164961 201985_at KIAA0196 E430025E21Rik 
ENSG00000165023 219619_at DIRAS2 Diras2 
ENSG00000165304 204825_at MELK Melk 
ENSG00000165609 223100_s_at NUDT5 Nudt5 
ENSG00000165868 214434_at HSPA12A Hspa12a 
ENSG00000166073 227846_at GPR176 Gpr176 
ENSG00000166165 200884_at CKB Ckb 
ENSG00000166224 212322_at SGPL1 Sgpl1 
ENSG00000166228 203557_s_at PCBD1 Pcbd1 
ENSG00000166278 203052_at C2 C2 
ENSG00000166311 209420_s_at SMPD1 Smpd1 
ENSG00000166387 212841_s_at PPFIBP2 Ppfibp2 
ENSG00000166401 206034_at SERPINB8 Serpinb8 
ENSG00000166402 228882_at TUB Tub 
ENSG00000166444 202440_s_at ST5 St5 
ENSG00000166546 214068_at BEAN1 Bean1 
ENSG00000166562 223299_at SEC11C Sec11c 
ENSG00000166681 217963_s_at NGFRAP1 Ngfrap1 
ENSG00000166710 216231_s_at B2M B2m 
ENSG00000166803 202503_s_at KIAA0101 2810417H13Rik 
ENSG00000166833 222599_s_at NAV2 Nav2 
ENSG00000166900 209238_at STX3 Stx3 
ENSG00000166908 218942_at PIP4K2C Pip4k2c 
ENSG00000166927 223343_at MS4A7 Ms4a7 
ENSG00000167004 208612_at PDIA3 Pdia3 
ENSG00000167106 212400_at FAM102A Fam102a 
ENSG00000167173 204494_s_at C15orf39 1700017B05Rik 
ENSG00000167460 209344_at TPM4 Tpm4 
Human ENSEMBL#        Probe on HU133+2.0  Human Gene Symbol Mouse Gene Symbol 
 
ENSG00000167535 209530_at CACNB3 Cacnb3 
ENSG00000167716 226738_at WDR81 Wdr81 
ENSG00000167900 1554408_a_at TK1 Tk1 
ENSG00000168038 232206_at ULK4 Ulk4 
ENSG00000168078 219148_at PBK Pbk 
ENSG00000168135 208359_s_at KCNJ4 Kcnj4 
ENSG00000168234 1570552_at TTC39C Ttc39c 
ENSG00000168374 201096_s_at ARF4 Arf4 
ENSG00000168398 205870_at BDKRB2 Bdkrb2 
ENSG00000168404 238025_at MLKL Mlkl 
ENSG00000168461 217762_s_at RAB31 Rab31 
ENSG00000168490 205325_at PHYHIP Phyhip 
ENSG00000168785 225388_at TSPAN5 Tspan5 
ENSG00000168917 219569_s_at TMEM22 Slc35g2 
ENSG00000169230 223032_x_at PRELID1 Prelid1 
ENSG00000169258 227975_at GPRIN1 Gprin1 
ENSG00000169299 223738_s_at PGM2 Pgm1 
ENSG00000169607 229610_at CKAP2L Ckap2l 
ENSG00000169679 215509_s_at BUB1 Bub1 
ENSG00000169783 227933_at LINGO1 Lingo1 
ENSG00000170011 214156_at MYRIP Myrip 
ENSG00000170266 201576_s_at GLB1 Glb1 
ENSG00000170312 210559_s_at CDK1 Cdk1 
ENSG00000170340 219326_s_at B3GNT2 B3gnt2 
ENSG00000170390 227666_at DCLK2 Dclk2 
ENSG00000170522 210868_s_at ELOVL6 Elovl6 
ENSG00000170540 211935_at ARL6IP1 Arl6ip1 
ENSG00000170579 206489_s_at DLGAP1 Dlgap1 
ENSG00000170915 227626_at PAQR8 Paqr8 
ENSG00000171189 207242_s_at GRIK1 Grik1 
ENSG00000171848 209773_s_at RRM2 Rrm2 
ENSG00000171951 204035_at SCG2 Scg2 
ENSG00000172071 218696_at EIF2AK3 Eif2ak3 
ENSG00000172548 230188_at NIPAL4 Nipal4 
ENSG00000172667 219628_at ZMAT3 Zmat3 
ENSG00000172725 64486_at CORO1B Coro1b 
ENSG00000172817 207386_at CYP7B1 Cyp7b1 
ENSG00000172986 235733_at GXYLT2 Gxylt2 
ENSG00000173083 222881_at HPSE Hpse 
ENSG00000173093 244833_at CCDC63 Ccdc63 
ENSG00000173821 225931_s_at RNF213 Rnf213 
ENSG00000174945 1562261_at AMZ1 Amz1 
ENSG00000175130 200644_at MARCKSL1 Marcksl1 
ENSG00000175175 236302_at PPM1E Ppm1e 
ENSG00000175183 211126_s_at CSRP2 Csrp2 
ENSG00000175197 209383_at DDIT3 Ddit3 
Human ENSEMBL#        Probe on HU133+2.0  Human Gene Symbol Mouse Gene Symbol 
 
ENSG00000175274 214667_s_at TP53I11 Trp53i11 
ENSG00000175899 217757_at A2M A2m 
ENSG00000176170 219257_s_at SPHK1 Sphk1 
ENSG00000176406 229823_at RIMS2 Rims2 
ENSG00000176771 239650_at NCKAP5 Nckap5 
ENSG00000176853 226294_x_at FAM91A1 D15Ertd621e 
ENSG00000176887 204915_s_at SOX11 Sox11 
ENSG00000176890 202589_at TYMS Tyms 
ENSG00000176978 224814_at DPP7 Dpp7 
ENSG00000177425 204005_s_at PAWR Pawr 
ENSG00000178718 223415_at RPP25 Rpp25 
ENSG00000178878 221031_s_at APOLD1 Apold1 
ENSG00000179051 224578_at RCC2 Rcc2 
ENSG00000179431 219522_at FJX1 Fjx1 
ENSG00000180537 230720_at RNF182 Rnf182 
ENSG00000181264 238497_at TMEM136 Tmem136 
ENSG00000181790 206083_at BAI1 Bai1 
ENSG00000182220 201444_s_at ATP6AP2 Atp6ap2 
ENSG00000182372 223912_s_at CLN8 Cln8 
ENSG00000182541 210582_s_at LIMK2 Limk2 
ENSG00000182612 223795_at TSPAN10 Tspan10 
ENSG00000182871 209081_s_at COL18A1 Col18a1 
ENSG00000182902 223605_at SLC25A18 Slc25a18 
ENSG00000183196 223786_at CHST6 Chst5 
ENSG00000183615 223657_at FAM167B Fam167b 
ENSG00000183696 203234_at UPP1 Upp1 
ENSG00000183765 210416_s_at CHEK2 Chek2 
ENSG00000183856 229538_s_at IQGAP3 Iqgap3 
ENSG00000184117 201709_s_at NIPSNAP1 Nipsnap1 
ENSG00000184575 212160_at XPOT Xpot 
ENSG00000184792 221237_s_at OSBP2 Osbp2 
ENSG00000184867 203404_at ARMCX2 Armcx2 
ENSG00000184992 231810_at BRI3BP Bri3bp 
ENSG00000185222 217975_at WBP5 Wbp5 
ENSG00000185339 204043_at TCN2 Tcn2 
ENSG00000185340 31874_at GAS2L1 Gas2l1 
ENSG00000185480 227928_at C12orf48 Parpbp 
ENSG00000185518 205551_at SV2B Sv2b 
ENSG00000185803 218151_x_at GPR172A Slc52a2 
ENSG00000185896 201553_s_at LAMP1 Lamp1 
ENSG00000185950 209184_s_at IRS2 Irs2 
ENSG00000187164 221802_s_at KIAA1598 4930506M07Rik 
ENSG00000187210 205505_at GCNT1 Gcnt1 
ENSG00000187266 396_f_at EPOR Epor 
ENSG00000187672 213938_at ERC2 Erc2 
ENSG00000188042 202208_s_at ARL4C Arl4c 
Human ENSEMBL#        Probe on HU133+2.0  Human Gene Symbol Mouse Gene Symbol 
 
ENSG00000189067 200706_s_at LITAF Litaf 
ENSG00000196136 202376_at SERPINA3 Serpina3n 
ENSG00000196208 205862_at GREB1 Greb1 
ENSG00000196405 227232_at EVL Evl 
ENSG00000196526 203563_at AFAP1 Afap1 
ENSG00000196562 224724_at SULF2 Sulf2 
ENSG00000196576 208890_s_at PLXNB2 Plxnb2 
ENSG00000196935 233888_s_at SRGAP1 Srgap1 
ENSG00000196950 225295_at SLC39A10 Slc39a10 
ENSG00000197081 201393_s_at IGF2R Igf2r 
ENSG00000197355 214755_at UAP1L1 Uap1l1 
ENSG00000197444 219277_s_at OGDHL Ogdhl 
ENSG00000197535 227761_at MYO5A Myo5a 
ENSG00000197629 226818_at MPEG1 Mpeg1 
ENSG00000197971 225407_at MBP Mbp 
ENSG00000198648 202786_at STK39 Stk39 
ENSG00000198715 1558693_s_at C1orf85 0610031J06Rik 
ENSG00000198794 212699_at SCAMP5 Scamp5 
ENSG00000198805 201695_s_at PNP Pnp 
ENSG00000198814 214681_at GK Gyk 
ENSG00000198901 218009_s_at PRC1 Prc1 
ENSG00000204386 208926_at NEU1 Neu1 
ENSG00000204681 205890_s_at GABBR1 Gabbr1 
ENSG00000205060 238418_at SLC35B4 Slc35b4 
ENSG00000205208 235088_at C4orf46 4930579G24Rik 
ENSG00000205336 212070_at GPR56 Gpr56 
ENSG00000213186 227801_at TRIM59 Trim59 
ENSG00000213614 201765_s_at HEXA Hexa 
ENSG00000213719 208659_at CLIC1 Clic1 
ENSG00000216490 201422_at IFI30 Ifi30 
ENSG00000219438 237094_at FAM19A5 Fam19a5 
ENSG00000225190 212717_at PLEKHM1 Plekhm1 
ENSG00000241973 213408_s_at PI4KA Pi4ka 
ENSG00000243649 202357_s_at CFB Gm20547 
ENSG00000244607 1554023_s_at CCDC13 Ccdc13 
ENSG00000247746 237247_at USP51 Usp51 
ENSG00000248905 238621_at FMN1 Fmn1 
ENSG00000249481 239870_at SPATS1 Spats1 
 
Supplemental Experimental Procedures 
Mice 
All mouse work was performed with the approval of the institutional animal care 
and use committee and in accordance with international legal and ethical norms. The 
EWSR1-ATF1, SS18-SSX2, and LacZ mice were previously described (Haldar et al., 
2007; Soriano, 1999; Straessler et al., 2013), as were Rosa26-CreER and Prx1-
CreERT2 mice (Badea et al., 2003; Hasson et al., 2007). The full length cDNA of type 2 
ASPSCR1-TFE3 was reverse transcribed from total RNA isolated from a human ASPS. 
The Rosa26-LSL-AT3 targeting vector was electroporated into R1 mouse embryonic 
stem cells. Clones were screened by long range PCR (CCT AAA GAA GAG GCT GTG 
CTT TGG and CAG TAG TCC AGG GTT TCC TTG ATG; GTG CAG TGT TGA GGG 
CAA TCT G and TAT GGC TTC TGA GGC GGA AAG A), then subjected to Southern 
blot analysis. Cells from a targeted clone were microinjected into C57BL/6 blastocysts. 
Resulting chimeras were mated to C57BL/6 mice and their offspring genotyped by long-
range PCR. 
Subsequent generations were PCR genotyped using tail-tip DNA:  Forward – 
GTT ATC AGT AAG GGA GCT GCA GTG G, Reverse targeted – AAG ACC GCG AAG 
AGT TTG TCC TC, Reverse wild-type – GGC GGA TCA CAA GCA ATA ATA ACC. 30 
cycles of 95°C for 30 seconds, 59°C for 45 seconds and 72°C for 30 seconds yield a 
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Imaging 
 Radiographs were obtained using a Kodak Carestream 4000 Pro Fx (Carestream 
Health, Inc., Rochester, NY, USA). Gross images were obtained with a Leica AF6000 
(Leica Microsystems, Wetzlar, Germany) and photomicrographs with an Olympus BX43 
scope and DP26 camera (Olympus America, Center Valley, PA, USA). 
 
Histology 
Tissues were harvested post-mortem, fixed in 10% buffered formalin overnight, 
embedded in paraffin following serial dehydration in ethanol, sectioned at 4µm and 
stained with H&E. dPAS utilized a 45 minute digestion with diastase solution (ARUP, 
Salt Lake City, UT, USA) at 37°C, rinsing, staining in Schiff reagent (ARUP) for 30 
minutes, rinsing, and hematoxylin counterstaining. Immunohistochemistries following 1-
hour pH8.0 cell conditioning 1 (Ventana Medical Systems, Tuscon, AZ, USA) antigen 
retrieval, proceeded for human TFE3 (Cell Marque, clone MRQ-37, rabbit polyclonal, 
1:100 dilution for 2 hours at 37°C), Cd31 (Abcam, rabbit polyclonal, 1:25 dilution for 2 
hours at 37°C), and Ki-67 (Abcam, rabbit polyclonal, 1:250 dilution for 2 hours at room 
temperature) using the BenchMark Ultra automated immunostainer (Ventana Medical 
Systems) with a biotinylated secondary antibody, DAB detection (IView) and 
hematoxylin counterstain. 
For assessment of hypoxia, Rosa26LSL-AT3/CreER mice received IP 60mg/kg 
pimonidazole 90 minutes prior to euthanasia. Tumors, skin, kidney, brain, and liver were 
rapidly collected and fixed in 10% formalin at 4°C overnight, serially dehydrated, 
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against mouse Hif1α (Novus Biologicals, H1alpha67 clone, dilution 1:500 for overnight 
at room temperature) or pimonidazole-thiol adducts (Hypoxyprobe monoclonal antibody, 
1:50 dilution for 1 hour at room temperature) was performed following 20 minute heat 
antigen retrieval and using IgG-horse radish peroxidase goat anti-rabbit secondary 
(1:250 dilution, 1 hour at room temperature) with DAB detection and hematoxylin 
counterstain. 
For X-gal staining, mice received IP 20mg/kg tamoxifen (Sigma-Aldrich, St. 
Louis, MO, USA) on days 14, 16, and 18 of life. Cranium and limbs harvested on day 21 
were fixed for 1 hour in 4% paraformaldehyde, decalcified for 2 weeks in pH7.4 14% 
ethylenediaminetetracetic acid at 4°C, dehydrated in glucose gradients, and embedded 
in OCT (Sakura Finetek, Torrance, CA, USA). 8µm-thick mid-sagittal sections of the 
cranium or shoulder were fixed with glyceraldehyde 0.25% for 10 minutes, washed 
thrice, and then incubated at 37°C for 8 hours in Xgal 1mg/mL with 30 mM potassium 
ferricyanide, 30 mM potassium ferrocyanide, 0.01% sodium deoxycholate, 0.02% 
Nonidet P-40 and 1 mM MgCl2. After rinsing in saline and distilled water, they were 
counterstained in nuclear fast red (Sigma). 
 
Tissue lactate measurement 
 Tissues were harvested at 2 months from 5 wild-type mice, snap frozen in liquid 
nitrogen, weighed, homogenized into 4.2% perchloric acid (ARUP) at 4°C, and 
centrifuged. 150uL of the supernatant was added to 900uL of a solution of 0.4M 
hydrazine (Fisher, Pittsburgh, PA, USA) and 0.5M glycine (Fisher) buffered by 
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(Fisher), with 14 units/mL L-lactate dehydrogenase from bovine heart (Sigma) and 
1.83mg/mL oxidized nicotinamide adenine dinucleotide (Fisher). Reactions were 
incubated at 35°C in parallel with triplicate reactions using lithium lactate concentration 
standards in 0.05% sulfuric acid. Absorbance at 340nm was measured with a 
Spectramax M5e (Molecular Devices Corporation, Sunnyvale, CA, USA) plate reader, 
lactate concentrations calculated for each sample from the standard curve, and 
normalized by the input tissue mass to generate tissue lactate concentrations. 
Reactions and standards were repeated for confirmation. 
 
Clinical 
With the approval of the institutional review board and in accordance with all 
international legal and ethical standards, fresh surgical specimens from consenting 
patients were placed in RNA-Later (Invitrogen) at 4°C overnight prior to long term 
storage at -80°C. Cases were annotated with histopathology, molecular, and clinical 
data. 5 ASPS cases and 3 uninvolved quadriceps samples were analyzed.  
 
Transcriptome analysis 
Total RNA was isolated using the RNeasy mini kit (Qiagen, Valencia, CA, USA). 
For sequencing, RNA was prepared using an Illumina TruSeq RNA kit (Illumina, Inc., 
San Diego, California) and checked with an Agilent Bioanalyzer RNA 6000 chip (Agilent 
Technologies, Santa Clara, California). mRNAs were captured using the Ribo-Zero 
method (Illumina) and fragmented. Library quality was then checked by Nanodrop 
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primers, and another bioanalyzer run. Sequencing was performed on an Illumina HiSeq 
2000 (Illumina) using a 50 cycle single end read. PhiX control library reads were added 
to each lane for quality assurance. Reads were aligned to the mm10 mouse or the hg19 
human genome builds. The OverdispersedRegionScanSeqs script in the USeq package 
(Nix et al., 2008) calculated the expression levels of ENSEMBL genes in FPKM values. 
USeq also discovers differentially expressed genes between two RNA-seq libraries by 
calling the DESeq R package (Anders and Huber, 2010). Internally, the DESeq 
algorithm uses a negative binomial distribution to model the read coverage, which is 
robust to the between-libraries variations of RNA-seq data by using biological replicate 
data. 
GEO data were normalized by DChip (Li and Hung Wong, 2001). GSEA was 
performed with Broad Institute software (Mootha et al., 2003; Subramanian et al., 2005). 
The Harris hypoxia gene set is curated by the Broad Institute (Harris, 2002), as is 
MitoCarta, including the original 1098 mouse genes, whose proteins localize to the 
mitochondria, and their 1013 human homologues (Pagliarini et al., 2008). Gene 
ontology analysis was performed with GO-Elite software (Zambon et al., 2012). 
 
Tissue Culture 
 The ASPS-1 cell line was cultured in Dulbecco’s Modified Eagle Medium with 
F12 Glutamax (DMEM/F12 from Life Technologies) with 10% fetal bovine serum (FBS 
from Life Technologies). The FU-UR-1 cell line was cultured in DMEM/F12+15%FBS. 
For tissue culture, CHC (Sigma) was dissolved as a 1.5M solution in DMSO and sodium 
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as 5000 cells seeded into each 96-well plate well, with lactate added 24 hours later.  
CellTiter-Glo (Promega) assay, applied using manufacturer’s recommended protocol, 
determined relative viability on a Perkin-Elmer Envision 2104 multilabel reader at 48 
hours for the faster growing FU-UR-1 cells and 72 hours for the slower growing ASPS-1 
cells. For Westerns, plates were quickly chilled, the media aspirated and replaced with 
4°C PBS, and cells collected by scraping and centrifuged to remove excess PBS. The 
NE-PER Nuclear and Cytoplasmic Extraction assay (Pierce) was then used according 
to the recommended protocol to isolate the nuclear and cytoplasmic fractions of total 
protein. After running and transferring to nitrocellulose, the membrane was divided for 
an overnight GAPDH control and HIF1α experimental antibody (Novus Biologicals) after 
blocking for an hour in 5% milk.  Imaging used a Bio-Rad ChemiDoc MP system. 
 
Metabolic phenotyping 
Tissue sections obtained immediately post mortem from tumors in mice of each 
genotype were placed in microwells per the manufacturer’s instructions for assessment 
on the Seahorse XF24 (Seahorse Bioscience, Massachusetts, USA). Minimal initial 
media included 2mM glucose in DMEM.  An injection of 10mM sodium lactate was 
timed and the subsequent oxygen consumption rate measured 24 minutes later. 
 
Lactate administration in vivo 
Isotonic sterile sodium lactate (Sigma) or sodium chloride (Sigma) was administered IP 
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